Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-01-12 Purchase |
2022-01-14 12:02 pm |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
155,039 | $12.6 | $1,953,491 | 7,075,233 (Indirect Direct) |
View |
| 2021-10-01 Sale |
2021-10-04 5:55 pm |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
11,507 | $24.35 | $280,185 | 323,928 (Direct) |
View |
| 2021-09-15 Sale |
2021-09-17 4:44 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $24.77 | $123,845 | 533,969 (Direct) |
View |
| 2021-09-09 Sale |
2021-09-09 5:32 pm |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
5,000 | $25.54 | $127,700 | 221,182 (Direct) |
View |
| 2021-08-20 Sale |
2021-08-23 4:22 pm |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
10,000 | $23.47 | $234,700 | 226,182 (Direct) |
View |
| 2021-08-16 Sale |
2021-08-17 4:05 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $21 | $104,994 | 538,653 (Direct) |
View |
| 2021-07-15 Sale |
2021-07-16 4:14 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $21.55 | $107,753 | 543,653 (Direct) |
View |
| 2021-06-15 Sale |
2021-06-16 5:00 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $25.32 | $126,600 | 548,653 (Direct) |
View |
| 2021-06-09 Sale |
2021-06-11 5:48 pm |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
9,969 | $25.05 | $249,723 | 264,197 (Direct) |
View |
| 2021-05-18 Sale |
2021-05-20 5:19 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $30 | $150,000 | 553,653 (Direct) |
View |
| 2021-05-17 Sale |
2021-05-17 5:16 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $28.3 | $141,476 | 558,653 (Direct) |
View |
| 2021-04-15 Sale |
2021-04-16 4:07 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
10,000 | $32.05 | $320,517 | 563,653 (Direct) |
View |
| 2021-03-15 Sale |
2021-03-17 5:01 pm |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
2,798 | $38.05 | $106,471 | 110,035 (Direct) |
View |
| 2021-03-15 Sale |
2021-03-17 5:00 pm |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
20,513 | $38.57 | $791,271 | 4,706,057 (Indirect Direct) |
View |
| 2021-03-15 Sale |
2021-03-17 5:00 pm |
Allogene Therapeutics Inc. | ALLO | MOORE ALISON Chief Technical Officer |
6,164 | $38.14 | $235,089 | 102,574 (Direct) |
View |
| 2021-03-15 Sale |
2021-03-17 5:00 pm |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
16,623 | $37.95 | $630,798 | 551,451 (Direct) |
View |
| 2021-03-15 Sale |
2021-03-17 5:00 pm |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
8,053 | $38.23 | $307,889 | 1,223,826 (Indirect Direct) |
View |
| 2021-01-14 Sale |
2021-01-19 4:31 pm |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
30,000 | $31.52 | $945,469 | 1,231,511 (Indirect Direct) |
View |
| 2020-11-16 Sale |
2020-11-18 4:36 pm |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
15,000 | $32.88 | $493,146 | 1,261,511 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2021-09-20 6:25 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | PF Equity Holdings 2 B.V. 10% Owner |
0 | $0 | 22,032,040 (Direct) |
View |
| 2021-09-15 Exercise |
2021-09-17 4:44 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $0 | 533,969 (Direct) |
View |
| 2021-09-15 Exercise |
2021-09-17 4:44 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $2.27 | 533,969 (Direct) |
View |
| 2021-08-16 Exercise |
2021-08-17 4:05 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $0 | 538,653 (Direct) |
View |
| 2021-08-16 Exercise |
2021-08-17 4:05 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $2.27 | 538,653 (Direct) |
View |
| 2021-07-30 Option Award |
2021-08-03 5:37 pm |
N/A 2031-07-30 |
Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director |
51,054 | $0 | 51,054 (Direct) |
View |
| 2021-07-30 Option Award |
2021-08-03 5:32 pm |
N/A 2031-07-30 |
Allogene Therapeutics Inc. | ALLO | Barrett Elizabeth A. Director |
63,385 | $0 | 63,385 (Direct) |
View |
Ownership |
2021-08-03 5:28 pm |
N/A 2030-09-16 |
Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director |
0 | $0 | 3,000 (Direct) |
View |
| 2021-07-15 Exercise |
2021-07-16 4:14 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $0 | 543,653 (Direct) |
View |
| 2021-07-15 Exercise |
2021-07-16 4:14 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $2.27 | 543,653 (Direct) |
View |
| 2021-06-15 Exercise |
2021-06-16 5:00 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $0 | 548,653 (Direct) |
View |
| 2021-06-15 Exercise |
2021-06-16 5:00 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $2.27 | 548,653 (Direct) |
View |
| 2021-06-10 Option Award |
2021-06-11 5:48 pm |
N/A 2031-06-10 |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
28,015 | $0 | 264,197 (Direct) |
View |
| 2021-06-10 Option Award |
2021-06-11 5:46 pm |
N/A 2031-06-10 |
Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director |
28,015 | $0 | 28,015 (Direct) |
View |
| 2021-06-10 Option Award |
2021-06-11 5:45 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Humer Franz B Director |
16,498 | $0 | 147,714 (Direct) |
View |
| 2021-06-10 Option Award |
2021-06-11 5:43 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
16,498 | $0 | 243,885 (Direct) |
View |
| 2021-06-11 Gift |
2021-06-11 5:43 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
500,000 | $0 | 243,885 (Direct) |
View |
| 2021-05-24 Exercise |
2021-05-26 08:00 am |
N/A 2030-03-18 |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
27,410 | $0 | 5,766,665 (Direct) |
View |
| 2021-05-24 Exercise |
2021-05-26 08:00 am |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
27,410 | $18.22 | 5,766,665 (Direct) |
View |
| 2021-05-24 Exercise |
2021-05-26 08:00 am |
N/A 2030-03-18 |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
14,897 | $0 | 1,358,292 (Direct) |
View |
| 2021-05-24 Exercise |
2021-05-26 08:00 am |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
14,897 | $18.22 | 1,358,292 (Direct) |
View |
| 2021-05-24 Exercise |
2021-05-25 08:00 am |
N/A 2030-03-18 |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
379,066 | $0 | 6,920,193 (Direct) |
View |
| 2021-05-24 Exercise |
2021-05-25 08:00 am |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
379,066 | $18.22 | 6,920,193 (Direct) |
View |
| 2021-05-18 Option Award |
2021-05-20 5:22 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
200,534 | $0 | 335,435 (Direct) |
View |
| 2021-05-18 Exercise |
2021-05-20 5:19 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $0 | 553,653 (Direct) |
View |
| 2021-05-18 Exercise |
2021-05-20 5:19 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $2.27 | 553,653 (Direct) |
View |
| 2021-05-17 Exercise |
2021-05-17 5:16 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $0 | 558,653 (Direct) |
View |
| 2021-05-17 Exercise |
2021-05-17 5:16 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
5,000 | $2.27 | 558,653 (Direct) |
View |
| 2021-04-15 Exercise |
2021-04-16 4:07 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
10,000 | $0 | 563,653 (Direct) |
View |
| 2021-04-15 Exercise |
2021-04-16 4:07 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
10,000 | $2.27 | 563,653 (Direct) |
View |
| 2020-08-31 Gift(A) |
2021-04-02 4:11 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
205,778 | $0 | 4,342,021 (Indirect) |
View |
| 2021-03-26 Option Award |
2021-03-30 5:00 pm |
N/A 2031-03-26 |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
252,858 | $0 | 6,740,350 (Direct) |
View |
| 2021-03-26 Option Award |
2021-03-30 4:57 pm |
N/A 2031-03-26 |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
379,288 | $0 | 5,085,345 (Direct) |
View |
| 2021-03-26 Option Award |
2021-03-30 4:55 pm |
N/A 2031-03-26 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
104,671 | $0 | 503,822 (Direct) |
View |
| 2021-03-26 Option Award |
2021-03-30 4:53 pm |
N/A 2031-03-26 |
Allogene Therapeutics Inc. | ALLO | MOORE ALISON Chief Technical Officer |
117,231 | $0 | 219,805 (Direct) |
View |
| 2021-03-26 Option Award |
2021-03-30 4:51 pm |
N/A 2031-03-26 |
Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer |
117,231 | $0 | 1,341,057 (Direct) |
View |
| 2021-03-26 Option Award |
2021-03-30 4:47 pm |
N/A 2031-03-26 |
Allogene Therapeutics Inc. | ALLO | Amado Rafael EVP of R&D and CMO |
117,231 | $0 | 227,266 (Direct) |
View |
| 2021-03-15 Exercise |
2021-03-17 5:00 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
10,000 | $0 | 551,451 (Direct) |
View |
| 2021-03-15 Exercise |
2021-03-17 5:00 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
10,000 | $2.27 | 551,451 (Direct) |
View |
| 2020-10-21 Ownership |
2021-02-03 4:22 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
305,918 | $0 | 727,387 (Direct) |
View |
| 2020-12-17 Exercise |
2020-12-18 4:34 pm |
N/A 2028-06-25 |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
51,500 | $0 | 567,702 (Direct) |
View |
| 2020-12-17 Exercise |
2020-12-18 4:34 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel |
51,500 | $2.27 | 567,702 (Direct) |
View |